Tech Company Financing Transactions
Hangzhou Chance Pharmaceuticals Funding Round
Hangzhou Chance Pharmaceuticals secured a funding round on 3/17/2025. Investors included HEDA Ventures.
Transaction Overview
Company Name
Announced On
3/17/2025
Transaction Type
Venture Equity
Amount
Unknown
Round
Undisclosed
Investors
Proceeds Purpose
The company intends to use the funds to support the advancement of Phase III clinical trials for CXG87, an improved formulation of budesonide/formoterol inhalation powder, as well as the development of new inhalation powder formulations.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Building 18, Yinhai Science and Technology Innovation Center 501
Hangzhou City, Zhejiang Province, Undisclosed
China
Hangzhou City, Zhejiang Province, Undisclosed
China
Phone
Email Address
Overview
Chance Pharmaceuticals is a clinical-stage biotechnology company focusing on discovering, developing and commercializing transformative inhalation therapies for the world's most debilitating diseases. Founded in 2015 by a team of passionate and experienced experts in inhalation therapy, our vision is to harness the potential of inhalation therapy to improve and transform the lives of people living with the diseases for which more treatment options are needed.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Donghao Chen
VP - Bus. Development
Guobao Zhao
VP - Operations
Peng Huang
VP - R & D
Lan Chen
VP - R & D
Pingping Lu
Browse more venture capital transactions:
Prev: 3/17/2025: Kela Technologies venture capital transaction
Next: 3/17/2025: Egle Therapeutics venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC transactions on this site are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs